Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

Impact of Adherence to Interferons in the Treatment of Multiple Sclerosis

(2010) Stephanie C. Steinberg et al.   CLINICAL DRUG INVESTIGATION

Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study

(2010) H. Tan et al.   Multiple Sclerosis Journal

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence

(2010) Francesco Patti   Patient Preference and Adherence

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis

(2009) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

(2009) Giancarlo Comi   CLINICAL THERAPEUTICS

A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

(2009) David W. Brandes et al.   CURRENT MEDICAL RESEARCH AND OPINION

Compliance, adherence, and the treatment of multiple sclerosis

(2009) Thomas Klauer et al.   JOURNAL OF NEUROLOGY

Factors that influence adherence with disease-modifying therapy in MS

(2009) Katherine Treadaway et al.   JOURNAL OF NEUROLOGY

Impact of Co-Prescribed Glatiramer Acetate and Antihistamine Therapy on the Likelihood of Relapse Among Patients with Multiple Sclerosis

(2009) Daniel A. Ollendorf et al.   JOURNAL OF NEUROSCIENCE NURSING

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

(2008) Jane Castelli-Haley et al.   ADVANCES IN THERAPY

Tolerability, adherence, and patient outcomes

(2008) A. P. Ross   NEUROLOGY

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH